BioLineRx (BLRX) Amortization (2014 - 2025)

BioLineRx's Amortization history runs 12 years deep, the most recent figure standing at $4.2 million for Q4 2025.

• In Q4 2025, Amortization fell 78.82% year-over-year to $4.2 million; the TTM figure through Dec 2025 stood at $3.1 million (down 89.48% YoY), while the FY2025 annual figure was -$2.0 million, up 78.03% from the prior year.
• Amortization was $4.2 million for Q4 2025 at BioLineRx, up from -$7.7 million in the prior quarter.
• In the past five years, Amortization ranged from a high of $20.0 million in Q4 2024 to a low of -$13.4 million in Q1 2024.
• Historically, Amortization has averaged $2.8 million across 5 years, with a median of $1.7 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Amortization jumped 1686.13% in 2023, then plunged 423.52% in 2024.
• A 5-year view of Amortization shows it stood at -$1.8 million in 2021, then jumped by 33.74% to -$1.2 million in 2022, then surged by 1686.13% to $18.9 million in 2023, then gained by 6.0% to $20.0 million in 2024, then sank by 78.82% to $4.2 million in 2025.
• The last three Amortization figures came in at $4.2 million (Q4 2025), -$7.7 million (Q1 2025), and $20.0 million (Q4 2024), per Business Quant data.